Abstracts tagged "axial spondyloarthritis"

Abstract Number: 2745 • 2016 ACR/ARHP Annual Meeting
Adult Axial Spondyloarthritis Screening and Referral Practices Amongst Primary Care Physicians, Physiotherapists, Chiropractors and Nurse Practitioners: Results from a Qualitative Study
Laura Passalent^1,2, Leslie Soever^2,3, Kathleen Bednis¹, Christopher Hawke^1,4, Andrew Bidos^5,6, Jeff Bloom^7,8, Y. Raja Rampersaud^6,8, Nigil Haroon^9,10 and Robert D Inman^8,9, ¹Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ²Physical Therapy, University of Toronto, Toronto, ON, Canada, ³MSK, Geriatrics and Cardiac Rehab Programs, University Health Network, Toronto, ON, Canada, ⁴Department of Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁵Health Quality Programs - ISAEC, University Health Network, Toronto, ON, Canada, ⁶Orthopaedics, Toronto Western Hospital, Toronto, ON, Canada, ⁷Family Medicine, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ¹⁰Rheumatology, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: For the axial spondyloarthritis (SpA) population, early recognition is crucial in preventing major morbidity. Despite this, there exists an unacceptably long delay between the…
Abstract Number: 688 • 2016 ACR/ARHP Annual Meeting
Spondyloarthritis Research Consortium of Canada (SPARCC) Baseline MRI SI Joint Score ≥2 Better Predicts Response to Golimumab Than Does Assessment of Spondyloarthritis International Society (ASAS) MRI Positivity in Nonradiographic Axial Spondyloarthritis
Walter Maksymowych¹, Anjela Tzontcheva², George Philip², Gina Bergman², Susan Huyck² and Sean P. Curtis², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Golimumab (GLM) was shown to be effective for nonradiographic axial spondyloarthritis (nr-axSpA) in a randomized, double-blind, placebo-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 The SPondyloArthritis…
Abstract Number: 2754 • 2016 ACR/ARHP Annual Meeting
Self-Reported Physical Activity Questionnaire in Axial Spondyloarthritis: Modification of the Squash
Fiona Maas¹, Anna Jetske Baron^1,2, Freke Wink³, Reinhard Bos³, Yvo Kamsma², Hendrika Bootsma⁴, Suzanne Arends^1,3 and Anneke Spoorenberg^1,3, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Improvement of physical function and physical activity are important goals in the management of axial spondyloarthritis (axSpA). Although physical function is included in the…
Abstract Number: 697 • 2016 ACR/ARHP Annual Meeting
Does Axial Spondyloarthritis Phenotype Correlate with Imaging Morphotype?
Xenofon Baraliakos¹, Annette Szumski², Heather Jones³ and Lianne S. Gensler⁴, ¹Rheumazentrum, Ruhr University, Bochum, Germany, ²inVentiv Health, Princeton, NJ, ³Inflammation & Immunology, Pfizer, Collegeville, PA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Traditionally, radiographic imaging was used to describe morphological differences between various types of axial SpA (axSpA). MRI has advanced understanding of disease, enabled earlier…
Abstract Number: 2779 • 2016 ACR/ARHP Annual Meeting
Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Maxime Dougados¹, Desiree van der Heijde², Wen-Chan Tsai³, Diego Saaibi⁴, Randi Bonin⁵, Lisa Marshall⁶, Heather Jones⁷, Ronald Pedersen⁸, Bonnie Vlahos⁹ and Miriam Tarallo¹⁰, ¹Rheumatology, Paris Descartes University, Paris, France, ²Leiden University Medical Center, Leiden, Netherlands, ³Kaohsiung Medical University, Kaohsiung City, Taiwan, ⁴MEDICITY S.A.S, Bucaramanga, Colombia, ⁵Clinical Affairs, Pfizer, Collegeville, PA, ⁶Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁷Inflammation & Immunology, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁰GHV, Pfizer, Rome, Italy
Background/Purpose: Few studies have evaluated the relationship between disease activity/clinical response and patient-reported outcomes (PROs) of pain, fatigue, health-related quality of life (HRQoL), and work…
Abstract Number: 706 • 2016 ACR/ARHP Annual Meeting
Performance of the ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis – a Systematic Literature Review and Meta-Analysis
Alexandre Sepriano¹, Roxana Rubio¹, Sofia Ramiro¹, Robert Landewé² and Désirée van der Heijde³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has developed and validated classification criteria for axial spondyloarthritis (axSpA) and peripheral SpA (pSpA). Following their release,…
Abstract Number: 3010 • 2016 ACR/ARHP Annual Meeting
Improvement of Spinal Inflammation Induced By Etanercept in Enthesitis Related Arthritis JIA-Patients. Data of the Reminder-Study
Gerd Horneff¹, Ivan Foeldvari², Kirsten Minden^3,4, Hans-Iko Huppertz⁵ and Ariane Klein⁶, ¹Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ²Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ³Epidemiology, Charite, DRFZ, Berlin, Germany, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: The data of the REMINDER study, a two-part, 48-week, randomized, placebo-controlled, double-blind withdrawal study on efficacy of etanercept (ETA) compared to placebo (PLC) in…
Abstract Number: 733 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Non-Biological Therapy (Non-Biological Drugs and Non-Pharmacological Interventions): A Systematic Literature Review for the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis
Andrea Regel¹, Alexandre Sepriano², Xenofon Baraliakos¹, Désirée van der Heijde², Juergen Braun¹, Robert Landewé³, Filip van Den Bosch⁴ and Sofia Ramiro², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose: As part of the 2016 update of the ASAS/EULAR recommendations for the management of axSpA, we performed a systematic literature review (SLR) to assess…
Abstract Number: 3037 • 2016 ACR/ARHP Annual Meeting
Calprotectin Is Highly Upregulated in Inflamed Axial Entheses in SKG Mice
Zheni Stavre¹, Yukiko Maeda² and Ellen M. Gravallese³, ¹Internal Medicine-Rheumatology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA, ³Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: SKG mice exhibit features of spondyloarthropathy (SpA) and inflammatory bowel disease (IBD). Their SpA-like phenotype is induced by a beta-glucan, curdlan, via the Dectin-1…
Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…
Abstract Number: 3162 • 2016 ACR/ARHP Annual Meeting
Symmetric and Asymmetric Sacroiliitis Are Associated with Different Major Histocompatibility Class I Alleles in Psoriatic Arthritis
Jon T. Giles¹, Muhammad Haroon², Deepak R. Jadon³, Raj Sengupta⁴, Alison L Nightingale⁵, Eleanor Korendowych³, Jing Bi⁶, Neil J. McHugh³, Oliver FitzGerald⁷ and Robert Winchester⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Kerry General Hospital, Co Kerry, Ireland, ³Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases,, Bath, United Kingdom, ⁵Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁶Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁷St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland
Background/Purpose: HLA-B27 has been linked to sacroiliitis (SII) in psoriatic arthritis (PsA); however, the contribution to SII of other human leukocyte antigen (HLA) Class I…
Abstract Number: 1042 • 2016 ACR/ARHP Annual Meeting
Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Xenofon Baraliakos², Kay-Geert Hermann³, Robert Landewé⁴, Pedro Machado⁵, Walter Maksymowych⁶, Owen Davies⁷, Natasha de Peyrecave⁷, Bengt Hoepken⁸, Lars Bauer⁸, Tommi Nurminen⁸ and Jürgen Braun⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, Academic Medical Center, Amsterdam & Zuyderland Medical Center Heerlen, Amsterdam, Netherlands, ⁵Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ⁶Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: RAPID-axSpA (NCT01087762) was a long-term study in patients (pts) with axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP). This is the first report of…
Abstract Number: 1163 • 2016 ACR/ARHP Annual Meeting
Impact of E-Learning on Perceived Social Role Participation of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial
Daeria Lawson¹, Laura Passalent^2,3, Rita Kang⁴, Christopher Hawke^2,5, Ahmed Omar^6,7, Arane Thavaneswaran¹, Nigil Haroon^8,9 and Robert D Inman^6,10, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ³Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁴Patient and Family Education, Toronto Western Hospital, Toronto, ON, Canada, ⁵Department of Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁹Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: The purpose of this study was to Methods: Fifty-six adult patients with axSpA attending a tertiary academic spondyloarthritis clinic were randomly assigned to one…
Abstract Number: 1164 • 2016 ACR/ARHP Annual Meeting
Impact of E-Learning on Knowledge, Self-Efficacy and Exercise Behaviours of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial
Laura Passalent^1,2, Rita Kang³, Daeria Lawson⁴, Christopher Hawke^1,5, Ahmed Omar^6,7, Arane Thavaneswaran⁴, Nigil Haroon^8,9 and Robert D Inman^7,10, ¹Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ²Physical Therapy, University of Toronto, Toronto, ON, Canada, ³Patient and Family Education, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Department of Physical Therapy, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁸Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁹Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a growing body of evidence to support the effectiveness of education programs for patients with arthritis. Despite this, there has been little development…
Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].